Breaking News Instant updates and real-time market news.

A

Agilent

$74.94

(0.00%)

, AXP

American Express

$119.17

(0.00%)

09:40
10/18/19
10/18
09:40
10/18/19
09:40

Unusually active option classes on open October 18th

Unusual total active option classes on open include: Agilent (A), American Express (AXP), Coca Cola (KO), CSX (CSX), US Steel (X), Johnson & Johnson (JNJ), Cronos Group (CRON), Schlumberger (SLB), Beyond Meat (BYND), and NIO (NIO).

A

Agilent

$74.94

(0.00%)

AXP

American Express

$119.17

(0.00%)

KO

Coca-Cola

$53.80

(0.00%)

CSX

CSX

$69.78

(0.00%)

X

U.S. Steel

$10.62

(0.00%)

JNJ

Johnson & Johnson

$136.20

(0.00%)

CRON

Cronos Group

$8.85

(0.00%)

SLB

Schlumberger

$31.90

(0.00%)

BYND

Beyond Meat

$117.50

(0.00%)

NIO

NIO Inc.

$1.47

(0.00%)

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 27

    Oct

  • 28

    Oct

  • 06

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 06

    Dec

  • 07

    Dec

A Agilent
$74.94

(0.00%)

08/19/19
NEED
08/19/19
NO CHANGE
Target $92
NEED
Buy
Agilent price target raised to $92 from $89 at Needham
Needham analyst Stephen Unger raised his price target on Agilent to $92 and kept his Buy rating after its "solid" Q3 results, also boosting his FY19 and FY20 EPS view by 2c to $3.08 and $3.39 respectively. The analyst is positive on the company's "diverse portfolio of solutions" addressing a variety of customer needs, with recent strategic investments targeting the shift in the pharma industry to biopharmaceuticals from small molecule drugs. Unger adds that the recent weakness in Agilent shares offer a "unique buying opportunity" for long-term investors.
10/08/19
CLVD
10/08/19
NO CHANGE
CLVD
Cleveland sees 'noticeable' slowdown in Life Science equipment demand
Cleveland Research analyst Steve Willoughby says his recent research suggests a "noticeable slowing" in Life Science equipment demand during Q3 in Europe, China, and parts of the U.S. The analyst who adjusted estimates for Thermo Fisher (TMO), Waters (WAT), Agilent (A), Mettler-Toledo (MTD), Avantor (AVTR), PerkinElmer (PKI) and Bruker (BRKR), believes a broader industry slowdown could impact industry multiples which he notes have expanded so far this year.
10/18/19
UBSW
10/18/19
DOWNGRADE
Target $82
UBSW
Neutral
Agilent downgraded to Neutral from Buy at UBS
UBS analyst Dan Brennan downgraded Agilent Technologies to Neutral from Buy with an unchanged price target of $82. The analyst likes many features of Agilent's profile, but sees risk of moderating growth due to the company's exposure to more cyclical end markets, namely chemical and energy, and instruments. At current levels Brennan views the stock's risk/reward as balanced given the limited upside to his price target.
08/15/19
BARD
08/15/19
NO CHANGE
Target $82
BARD
Outperform
Agilent price target raised to $82 from $79 at Baird
Baird analyst Catherine Schulte raised her price target on Agilent to $82 from $79 following strong Q3 results. The analyst noted its strong growth despite ongoing headwinds from China. She noted management raised guidance but she said there is likely a fair amount of conservatism baked in due to ongoing macro concerns. Schulte reiterated her Outperform rating on Agilent shares.
AXP American Express
$119.17

(0.00%)

07/22/19
BMOC
07/22/19
NO CHANGE
Target $119
BMOC
Market Perform
American Express price target raised to $119 from $114 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on American Express to $119 and kept his Market Perform rating after its Q2 results that showed lower credit and operating costs being offset by lower net interest margins and volumes. The analyst believes that the company's earnings growth will remain pressured by falling merchant discount rates and rising customer engagement costs, having "stalled" at about about 10%-11%.
07/10/19
WELS
07/10/19
NO CHANGE
Target $140
WELS
Outperform
American Express price target raised to $140 from $135 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for American Express to $140 from $135 ahead of quarterly results as he expects "meet and beats" into earnings from the card networks and issuers, as the U.S. consumer data points he tracks are holding up well. The analyst reiterates an Outperform rating on the shares.
07/22/19
RBCM
07/22/19
NO CHANGE
Target $125
RBCM
Sector Perform
American Express price target raised to $125 from $120 at RBC Capital
RBC Capital analyst Jon Arfstrom raised his price target on American Express to $125 after its Q2 earnings beat, saying the quarter benefited from a lower than expected loan loss provision and seasonally stronger billings and loan growth. The analyst further notes that the company's credit trends were stable and fundamentals remain solid. Arfstrom keeps his Sector Perform rating, adding that the stock may be an attractive long-term holding for investors seeking a high quality core holding, but his near-term neutral view balances the positive outlook with a premium valuation.
09/17/19
MSCO
09/17/19
NO CHANGE
Target $142
MSCO
Overweight
Morgan Stanley says American Express dip an overreaction to monthly credit stats
Morgan Stanley analyst Betsy Graseck noted that American Express shares dipped a bit over 1% on Monday, which she said was due to an "overreaction" to the August master trust data that showed a slight uptick in charge-offs and a continued deceleration in loan growth. Her model changes prompted Graseck to lower her Q3 EPS forecast by 1c to $2.05, which she noted is still slightly above consensus. Graseck has an Overweight rating and $142 price target on AmEx shares.
KO Coca-Cola
$53.80

(0.00%)

10/02/19
GUGG
10/02/19
DOWNGRADE
Target $60
GUGG
Neutral
Guggenheim downgrades Monster Beverage to Neutral as Coke Energy comes to U.S.
As previously reported, Guggenheim analyst Laurent Grandet downgraded Monster Beverage (MNST) to Neutral from Buy given his view that the stock will be range-bound until the market can better gauge the impact of the upcoming U.S. launch of Coca-Cola (KO) Energy, which is planned for January. In Europe, where Coke has already launched Energy, there are signs of softness for Monster, though there is also broader category slowdown there and the long-term impact is still unknown, added Grandet. He lowered his EPS estimates for Monster for FY19-FY21 and cut his price target on the shares to $60 from $74.
10/02/19
BMOC
10/02/19
NO CHANGE
Target $34
BMOC
Outperform
BMO Capital more optimistic about Keurig Dr Pepper generating merger synergies
BMO Capital analyst Amit Sharma is keeping his Outperform rating and $34 price target on Keurig Dr Pepper (KDP), citing its expected "sector leading" mid-teen earnings growth through 2021 along with his "greater confidence" in post-synergies earnings growth potential in high single digits. The analyst notes that investors are focusing on the company's coffee business while overlooking the "ingrained structural advantages" of its much-larger RTD beverage business, with consensus estimates modeling a "smaller" improvement than the expected North America sales trends at Coca-Cola (KO) and PepsiCo (PEP).
07/29/19
07/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Domino's Pizza (DPZ) initiated with a Sell at Deutsche Bank and a Neutral at Goldman Sachs. 2. Oaktree Specialty Lending (OCSL) initiated with a Neutral at Janney Montgomery Scott. 3. Chipotle (CMG) initiated with a Conviction Buy at Goldman Sachs, while McDonald's (MCD), Starbucks (SBUX), and Shake Shack (SHAK) were initiated with a Buy, Restaurant Brands (QSR) and Yum! Brands (YUM) were initiated with a Neutral, and Wendy's (WEN) and Jack in the Box (JACK) were initiated with a Sell. 4. PepsiCo (PEP) and Coca-Cola (KO) initiated with an Overweight at Atlantic Equities. 5. Dell Technologies (DELL) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/05/19
MSCO
08/05/19
NO CHANGE
MSCO
Coca-Cola added to Fresh Money Buy List at Morgan Stanley
Morgan Stanley equity strategist Michael Wilson said he is shifting the firm's "Fresh Money Buy List" to be more defensive by adding Coca-Cola (KO) and removing LyondellBasell (LYB). At Coke, he expects an acceleration in EPS growth driven by stronger pricing power, volume growth and new products, said Wilson. In terms of the broader market, Wilson said new tariffs are not the only thing driving the market lower, pointing to full valuations, corporate profits turning lower and technical resistance as other factors ahead of "heavy Treasury issuance this month" that will add another headwind.
CSX CSX
$69.78

(0.00%)

10/04/19
JPMS
10/04/19
NO CHANGE
JPMS
JPMorgan downgrades CSX and Echo Global, upgrades Hub Group
JPMorgan analyst Brian Ossenbeck downgraded both CSX (CSX) and Echo Global (ECHO) to Neutral from Overweight while upgrading Hub Group (HUBG) to Overweight from Neutral. The analyst sees downside risk to 2020 consensus estimates across the Transportation & Logistics sector. However, the truckload carriers should navigate the revisions well as the full truckload rate cycle gains momentum with help from the full implementation of electronic logging devices in mid-December, Ossenbeck tells investors in a research note. His upgrade of Hub Group to Overweight reflects his preference to add full truckload rate exposure at a "reasonable valuation." Further, the company's diverse business model should continue beating expectations in 2020, contends the analyst, who notes that Hub is now his top SMID cap idea. Ossenbeck's downgrade of Echo is based on expectations for continued margin compression in 2020 from its increasing tech investments and narrowing contract/spot spreads. His downgrade of CSX is based on valuation after the company's "tremendous run." The analyst's top rail pick remains Norfolk Southern (NSC).
10/04/19
JPMS
10/04/19
DOWNGRADE
Target $76
JPMS
Neutral
CSX downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Brian Ossenbeck downgraded CSX to Neutral from Overweight with a price target of $76, down from $83.
10/18/19
ARGS
10/18/19
NO CHANGE
Target $82
ARGS
Buy
Recent weakness in CSX offers buying opportunity, says Argus
Argus analyst John Eade is keeping his Buy rating and $82 price target on CSX after its Q3 earnings beat this week. The analyst notes that while the stock has underperformed the market over the past quarter and the past year, the weakness offers a buying opportunity. Eade cites the focus of the new CEO to lower the company's costs to adjust to the challenging current volume trends as well as its commitment to buybacks. The analyst further points to the CSX dividend hikes, which he believes signals its confidence in the company's long-term outlook.
07/26/19
07/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) and Citi (C) upgraded to Outperform from Market Perform at Keefe Bruyette. 2. Ambev (ABEV) upgraded to Neutral from Underweight at JPMorgan with analyst Lucas Ferreira saying the post-earnings share rally shows that investors are chasing good growth stories to play Brazil's economic recovery. 3. West Pharmaceutical (WST) upgraded to Neutral from Underperform at BofA/Merrill with analyst Derik de Bruin saying that over the course of the first half, the company addressed his prior concerns around organic revenue growth and product mix trends while also boosting its operating margins and generating higher free cash flows. 4. Union Pacific (UNP) upgraded to Overweight from Neutral at Atlantic Equities, while CSX (CSX) was upgraded to Neutral from Underweight. 5. Hasbro (HAS) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's dominant position with a range of "strong" brands as well as in the big-screen business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
X U.S. Steel
$10.62

(0.00%)

10/02/19
BMOC
10/02/19
NO CHANGE
Target $12
BMOC
Market Perform
U.S. Steel's Big River Steel deal is 'meaningful transaction', says BMO Capital
BMO Capital analyst David Gagliano says the $700M acquisition of Big River Steel by U.S. Steel is a "meaningful transaction" in that it provides the latter with a "low operating-cost, growth asset" which positions it better over the long term. The analyst is keeping his Market Perform rating and $12 on the stock however, noting that the debt-financed deal adds even more debt to U.S. Steel, which is is also paying a "fairly high" implied valuation.
09/23/19
09/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcoa (AA) downgraded to Neutral from Buy at Goldman Sachs. 2. Commercial Metals (CMC) was downgraded to Neutral from Buy at Goldman Sachs while Schnitzer Steel (SCHN) was downgraded to Sell from Neutral. 3. AK Steel (AKS) was downgraded to Underweight from Overweight at JPMorgan while Cleveland-Cliffs (CLF) and U.S. Steel (X) were downgraded to Neutral from Overweight. 4. Clorox (CLX) downgraded to Underweight from Equal Weight at Barclays. 5. Spirit Airlines (SAVE) downgraded to Equal Weight from Overweight at Stephens with analyst Jack Atkins saying with its heavy Southeast and Caribbean exposure, Spirit significantly lowered its Q3 guidance in early September due to Hurricane Dorian. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/19
JPMS
09/23/19
DOWNGRADE
JPMS
Underweight
JPMorgan double downgrades AK Steel, cuts U.S. Steel on flattish price outlook
JPMorgan analyst Michael Gambardella earlier today lowered his estimates and price targets for the steel companies to reflect a "more flattish" steel price environment. The analyst also double downgraded AK Steel (AKS) to Underweight from Overweight and downgraded U.S. Steel (X) to Neutral Overweight. He removed U.S. Steel from his firm's Analyst Focus List. The U.S. steel stocks and steel prices have been under pressure this year, which is largely due to concerns about supply additions planned for the next several years, continued uncertainty surrounding trade, and some softening in demand, Gambardella tells investors in a research note. Further, after a brief rebound, steel and scrap prices are now heading lower, adds the analyst. He kept Overweight ratings on Commercial Metals (CMC), Nucor (NUE), Steel Dynamics (STLD), and Stelco Holdings (STZHF).
09/23/19
JPMS
09/23/19
DOWNGRADE
Target $14
JPMS
Neutral
U.S. Steel downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Gambardella downgraded U.S. Steel to Neutral from Overweight and lowered his price target for the shares to $14 from $26.
JNJ Johnson & Johnson
$136.20

(0.00%)

10/16/19
JPMS
10/16/19
NO CHANGE
Target $38
JPMS
Overweight
JPMorgan boosts Jabil target to $38 on key customer momentum
JPMorgan analyst Paul Coster raised his price target for Jabil (JBL) to $38 from $36 and keeps an Overweight rating on the shares. The analyst increased Jabil's price-to-earnings multiple to reflect positive momentum at key end customers Johnson & Johnson (JNJ) and Apple (AAPL), and to reflect near-term prospects for a hiatus in the trade conflict between the U.S. and China. J&J's Q3 results point to solid medical device performance, and stronger than expected iPhone demand for both the 11 and legacy models "should buoy positive headline momentum" heading into Apple's earnings at the end of the month, Coster tells investors in a research note.
10/16/19
ATLE
10/16/19
UPGRADE
Target $129
ATLE
Neutral
Johnson & Johnson upgraded to Neutral from Underweight at Atlantic Equities
Atlantic Equities analyst Steve Chesney upgraded Johnson & Johnson to Neutral from Underweight with a $129 price target.
10/11/19
BERN
10/11/19
UPGRADE
Target $155
BERN
Outperform
Bernstein upgrades 'historically cheap' Johnson & Johnson to Outperform
Bernstein analyst Lee Hambright upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $155, up from $148. The shares in premarket trading are up $1.94, or 1.5%, to $131. The stock is "historically cheap," currently trading at a 17% discount to its sum-of-the-parts and a 13% discount to the S&P 500 Index, Hambright tells investors in a research note. The analyst, who believes J&J will resolve its legal liability for $10B-$12B, says the shares reflect a worst case scenario with $50B of liabilities being priced in. Following discussions with legal experts, Hambright has a "hard time seeing the worst-case scenarios playing out." The analyst estimates Johnson & Johnson faces about $5B of liability for opioids, another $5B for talc, and $800M for Risperdal.
10/16/19
10/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Underweight at Atlantic Equities. 2. FMC Corporation (FMC) upgraded to Outperform from Neutral at Baird with analyst Ben Kallo saying he believes FMC's new product introductions, expected share gains in key markets, and operating leverage can drive revenue and adjusted EBITDA growth in 2020 and beyond. 3. Pure Storage (PSTG) upgraded to Outperform from Market Perform at Raymond James with analyst Simon Leopold saying recent VAR/Distributor checks have reflected positive sentiment suggesting Pure can exceed current Street estimates and he has gained a greater appreciation for the market expansion offered by the new FlashArray//C. 4. PDF Solutions (PDFS) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab saying PDF Solutions is transitioning the company to an analytics software model, and believes that looking out 3-5 years, and in line with management's long term model shared at the company's Analyst Day, it can become a "Rule of 40" SaaS like company with 70% gross margins and in aggregate a 20% top line growth rate and 20% operating margin. 5. Builders FirstSource (BLDR) and BMC Stock Holdings (BMCH) upgraded to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRON Cronos Group
$8.85

(0.00%)

10/18/19
STFL
10/18/19
UPGRADE
STFL
Buy
Cronos Group upgraded to Buy from Hold at Stifel
Stifel analyst Andrew Carter upgraded Cronos Group (CRON) to Buy from Hold with a price target of C$14.00, down from C$16.50. The analyst Cronos is "unconstrained" in its ability to invest towards a $200B global opportunity with C$2B in cash on hand the resources of Altria Group (MO), Carter tells investors in a research note titled "Crowning a New King in the North." The analyst believes Cronos will show an "enhanced revenue growth profile" that leverages the distribution capabilities of Altria to build its U.S. CBD business and demonstrate "break-through product potential" in the Canadian vapor segment. Given the company's "advantaged and enhanced position," investors should buy Cronos shares following their recent pullback, says Carter.
10/16/19
BOFA
10/16/19
NO CHANGE
BOFA
BofA lowers cannabis stock price targets on further sales estimate changes
Following yesterday's rally in cannabis stock's driven by Aphria's (APHA) earnings, BofA Merrill Lynch analyst Christopher Carey said he doesn't see a case for sustainable upside yet until consensus estimates are cut further, which he thinks will ensue with the calendar Q3 results from the group. The reason that industry sales could be flat to down quarter-over-quarter sector-wide is that the cannabis industry is going from a period of inventory build to one of inventory "de-load," said Carey. Given his sales estimate revisions, he has lowered his price target on Aurora Cannabis (ACB) shares to $5 from $6, cut his Canopy Growth (CGC) price target to $23 from $27, trimmed his Cronos Group (CRON) target to $13 from $16 and decreased his Hexo (HEXO) target to $2 from $2.50. Carey keeps a Buy rating on Cronos, has Neutral ratings on Aurora and Canopy and maintains an Underperform rating on Hexo.
10/09/19
ROTH
10/09/19
NO CHANGE
ROTH
Roth says low enthusiasm for cannabis stocks doesn't reflect industry potential
Roth Capital analyst Scott Fortune noted that stocks in the cannabis sector have declined during the six months since the first quarter with the industry "mired in a capital crunch, with a vape crisis to make matters worse." However, he thinks the recently lower enthusiasm for cannabis stocks does not reflect the cannabis industry's prospects, as he still sees a lot of upside potential. A "meaningful shift" in investor focus to operational execution has led to a short-term correction in valuations, but the industry is still projected to grow at a 27% compound annual growth rate for the next three years, said Fortune, who advises that investors focus for now on companies with strong balance sheets and positive adjusted EBITDA who are nearing break even. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), and Trulieve Cannabis (TCNNF).
10/10/19
STFL
10/10/19
NO CHANGE
STFL
Hexo miss further damages cannabis industry credibility, says Stifel
Hexo (HEXO) this morning provided a preliminary update for its fiscal Q4 with revenue coming in below the consensus estimate and well below the "double" offered by management mid-quarter during the Q3 earnings call, Stifel analyst Andrew Carter tells investors in a research note. The preannouncement is "another headline damaging" the cannabis industry's credibility, Carter tells investors in a research note. For companies facing "significant financing risk," the analyst believes a "real segregation of assets will occur." Some companies will face significant dilution due to onerous financing terms while others will simply be unable to access capital, predicts the analyst. Carter thinks the macro environment will continue to be difficult and that the capital positions of Canopy Growth (CGC) and Cronos Group (CRON) are "clear competitive advantages." Those two have the ability to continue executing their business plans while capitalizing on the sector weakness, which "will only intensify from here," says Carter. Other names in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Zynerba (ZYNE). Shares of Hexo are down 24%, or 90c, to $2.78 in early trading.
SLB Schlumberger
$31.90

(0.00%)

09/16/19
09/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Raytheon (RTN) upgraded to Overweight from Neutral at JPMorgan with analyst Seth Seifman saying the stock's outperformance thus far in September is a sign of increasing investor confidence in the outlook for Raytheon and for the United Technologies (UTX) combination, along with some mean reversion. 2. Uber (UBER) and Lyft (LYFT) upgraded to Buy from Hold at HSBC. 3. Schlumberger (SLB) upgraded to Overweight from Equal Weight at Barclays with analyst J. David Anderson saying new CEO Olivier Le Peuch "hit all the right notes" as he repositions the company to succeed in a lower growth environment. 4. RE/MAX Holdings (RMAX) upgraded to Outperform from Market Perform at JMP Securities. 5. Esperion (ESPR) upgraded to Neutral from Sell at Goldman Sachs with analyst Paul Choi saying he now sees less risk of the launch performance of bempedoic acid disappointing over the intermediate term since 2019-2022 consensus revenue estimates have come down "meaningfully." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/19
SBSH
09/16/19
NO CHANGE
SBSH
Nabors, Schlumberger, Halliburton have material operations in Saudi, says Citi
Following the attacks on Saudi Arabia, Citi analyst Scott Gruber expects "most if not all" of the Upstream Energy complex could see an uplift. However, Nabors Industries (NBR), Schlumberger (SLB), Halliburton (HAL) and Valaris (VAL) have material operations in Saudi and could see activity slow given the magnitude of the outage, Gruber tells investors in a research note.
09/16/19
LEHM
09/16/19
UPGRADE
Target $50
LEHM
Overweight
Barclays upgrades Schlumberger after new CEO 'hit all the right notes'
Barclays analyst J. David Anderson upgraded Schlumberger to Overweight from Equal and raised his price target for the shares to $50 from $45. New CEO Olivier Le Peuch "hit all the right notes" as he repositions the company to succeed in a lower growth environment, Anderson tells investors in a research note. The analyst believes Le Peuch addressed the Street's biggest concerns while also providing "bold, yet achievable" financial targets. Anderson thinks long-only investors will start to pay attention after gaining confidence in the new direction of Schlumberger. The company is now best positioned among the Big 3, says the analyst.
09/16/19
LEHM
09/16/19
UPGRADE
Target $50
LEHM
Overweight
Schlumberger upgraded to Overweight from Equal Weight at Barclays
Barclays analyst J. David Anderson upgraded Schlumberger to Overweight from Equal and raised his price target for the shares to $50 from $45.
BYND Beyond Meat
$117.50

(0.00%)

10/14/19
10/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ping Identity (PING) initiated with an Outperform at Wells Fargo, Raymond James, Oppenheimer, Raymond James, RBC Capital, and William Blair, an Overweight at Barclays, as well as a Buy at Mizuho, Citi, BofA/Merrill, Goldman Sachs, Stifel, and Deutsche Bank. 2. Envista (NVST) initiated with an Outperform at Evercore ISI, an Overweight at JPMorgan, a Buy at Jefferies, Goldman Sachs, and Stifel, an Equal Weight at Morgan Stanley, as well as a Neutral at Credit Suisse and BofA/Merrill. 3. Datadog (DDOG) initiated with an Outperform at William Blair, an Overweight at JPMorgan and Barclays, a Buy at Stifel and Needham, an Equal Weight at Morgan Stanley, a Sector Perform at RBC Capital, a Market Perform at Raymond James and JMP Securities, a Neutral at Goldman Sachs, and a Hold at Jefferies. 4. Beyond Meat (BYND) initiated with a Market Perform on valuation at Wells Fargo. 5. Bloom Energy (BE) assumed with an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/19
WELS
10/14/19
INITIATION
Target $125
WELS
Market Perform
Beyond Meat initiated with a Market Perform on valuation at Wells Fargo
Wells Fargo analyst John Baumgartner initiated coverage of Beyond Meat with a Market Perform rating and $125 price target. The analyst believes Beyond Meat's growth potential is "fully discounted" into valuation and recommends waiting for increased visibility regarding competitive entrants and market adoption before owning shares.
09/26/19
WBLR
09/26/19
NO CHANGE
WBLR
Market Perform
William Blair encouraged, but not surprised, by McDonald's testing Beyond Meat
William Blair analyst Jon Andersen is not surprised by the announcement that McDonald's (MCD) will conduct a 12-week test in Canada of a plant-based burger made with patties from Beyond Meat (BYND). However, the analyst is encouraged by Beyond Meat's involvement, pointing out that many major burger chains have added plant-based options amid rising consumer interest and demand, and better product technology. This includes Carl's Jr. Beyond Famous Star burger, Burger King's new Impossible Whopper, and White Castle's Impossible slider, Andersen points out in a research note. He keeps a Market Perform rating on Beyond Meat, whose stock is up 13%, or $18.28, to $156.60 in early trading.
09/26/19
JEFF
09/26/19
NO CHANGE
Target $190
JEFF
Hold
Beyond Meat to 'squeeze sharply higher' after McDonald's news, says Jefferies
Jefferies analyst Kevin Grundy said McDonald's (MCD) interest in Beyond Meat (BYND) makes sense for both sides and the announcement of a trial by the burger giant "is what bulls have been waiting for" given McDonald's 38,000 worldwide locations. With short interest near 50% of float, he would expect Beyond Meat shares to "squeeze sharply higher," Grundy tells investors. If McDonald's were to pursue a broader roll-out in the U.S. of the "PLT" burgers, it could add greater than 40% to his current FY20 sales forecast on a run-rate basis, added Grundy, who keeps a Hold rating on Beyond Meat shares, citing valuation.
NIO NIO Inc.
$1.47

(0.00%)

10/04/19
10/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HP Inc. (HPQ) downgraded to Hold from Buy at Loop Capital with analyst Ananda Baruah citing HP's Analyst Day presentation disclosing strategic initiatives, job cuts, and a free cash flow guide of $3B in FY20 vs. $3.7B in FY21. 2. Insulet (PODD) downgraded to Neutral from Buy at UBS with analyst Matthew Taylor citing valuation. 3. NIO Inc. (NIO) downgraded to Neutral from Buy at Goldman Sachs with analyst Fei Fang saying Nio's share price has fallen 40% since September 24, when the company announced Q2 results, which Fang attributes to uncertainties about volume since Chinese EV sales have rapidly declined after the government reduced electric vehicle subsidies and about the company's capital structure and funding needs. 4. EchoStar (SATS) downgraded to Neutral from Buy at Citi with analyst Michael Rollins saying the company's lack of free cash flow and limited visibility on its future growth prospects will likely limit the potential for multiple expansion. 5. Ambarella (AMBA) resumed with a Hold from Buy at Stifel with analyst Tore Svanberg saying he believes inventory build in security surveillance, especially China, could limit near term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/19
GSCO
10/04/19
DOWNGRADE
GSCO
Neutral
NIO Inc. downgraded to Neutral from Buy at Goldman Sachs
09/26/19
WOLF
09/26/19
DOWNGRADE
Target $1.9
WOLF
Peer Perform
NIO Inc. downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Dan Galves downgraded NIO Inc. to Peer Perform from Outperform, stating that the company's cash burn was worse than expected in Q2 and its volume and margin guidance was "disappointing." The company's financing outlook has become "completely unclear" and the lack of a financing announcement along with earnings is "concerning," said the analyst, who set a $1.90 price target on the stock.
10/04/19
GSCO
10/04/19
DOWNGRADE
Target $1.47
GSCO
Neutral
Goldman Sachs downgrades NIO Inc. to Neutral, slashes target to $1.47 from $9.76
Goldman Sachs analyst Fei Fang downgraded NIO Inc. to Neutral from Buy with a price target of $1.47, down from $9.76. Nio's share price has fallen 40% since September 24, when the company announced Q2 results, which Fang attributes to uncertainties about volume since Chinese EV sales have rapidly declined after the government reduced electric vehicle subsidies and about the company's capital structure and funding needs. Fang maintains a 2023 estimate of the total addressable market for EVs in China of 1M new car sales, but lowered Nio's 2023 market share forecast to 15% from 25% due to more intense EV competition.

TODAY'S FREE FLY STORIES

10:30
12/10/19
12/10
10:30
12/10/19
10:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NLOK

NortonLifeLock

$26.29

0.86 (3.38%)

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Options
NortonLifeLock call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
UBS alternative energy windham to hold an analyst/industry conference call »

Alternative Energy &…

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
JPMorgan oil & gas analysts to hold an analyst/Industry conference call »

Large Cap Oil & Gas…

OMCL

Omnicell

$80.19

0.16 (0.20%)

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
Omnicell to host investor & analyst day »

Investor & analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

QSR

Restaurant Brands

$66.80

0.8 (1.21%)

, MCD

McDonald's

$194.64

-0.07 (-0.04%)

10:19
12/10/19
12/10
10:19
12/10/19
10:19
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

QSR

Restaurant Brands

$66.80

0.8 (1.21%)

MCD

McDonald's

$194.64

-0.07 (-0.04%)

SBUX

Starbucks

$87.36

1.08 (1.25%)

WEN

Wendy's

$21.59

-0.13 (-0.60%)

CMG

Chipotle

$822.75

-4.81 (-0.58%)

DNKN

Dunkin' Brands

$76.03

-0.2 (-0.26%)

EAT

Brinker

$41.77

-0.92 (-2.16%)

DPZ

Domino's Pizza

$286.82

0.23 (0.08%)

YUM

Yum! Brands

$98.95

-0.04 (-0.04%)

TXRH

Texas Roadhouse

$55.93

-0.22 (-0.39%)

ARAV

Aravive

$12.19

0.89 (7.88%)

BORR

Borr Drilling

$6.80

0.2 (3.03%)

AAXN

Axon

$72.49

0.22 (0.30%)

ZM

Zoom Video

$64.98

-0.94 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

  • 16

    Dec

NFLX

Netflix

$295.83

-6.65 (-2.20%)

, JPM

JPMorgan

$133.55

-0.9 (-0.67%)

10:18
12/10/19
12/10
10:18
12/10/19
10:18
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

NFLX

Netflix

$295.83

-6.65 (-2.20%)

JPM

JPMorgan

$133.55

-0.9 (-0.67%)

MKC

McCormick

$170.54

-2.155 (-1.25%)

CSX

CSX

$69.59

-0.82 (-1.16%)

VTR

Ventas

$56.78

-0.72 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

PH

Parker-Hannifin

$201.96

0.49 (0.24%)

, RDFN

Redfin

$20.98

0.21 (1.01%)

10:18
12/10/19
12/10
10:18
12/10/19
10:18
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

PH

Parker-Hannifin

$201.96

0.49 (0.24%)

RDFN

Redfin

$20.98

0.21 (1.01%)

MNRO

Monro

$78.70

4.24 (5.69%)

AGRO

Adecoagro

$7.98

0.47 (6.26%)

OI

Owens-Illinois

$10.51

0.22 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/10/19
12/10
10:17
12/10/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/10/19
12/10
10:16
12/10/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LK

Luckin Coffee

$30.72

0.35 (1.15%)

10:15
12/10/19
12/10
10:15
12/10/19
10:15
Options
Luckin Coffee put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTT

Qutoutiao

$2.70

-0.16 (-5.59%)

10:14
12/10/19
12/10
10:14
12/10/19
10:14
Hot Stocks
Qutoutiao sinks after short report claims 74% of sales are 'fake' »

Shares of Qutoutiao moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$43.80

0.515 (1.19%)

10:12
12/10/19
12/10
10:12
12/10/19
10:12
Conference/Events
Smartsheet management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

SFIX

Stitch Fix

$27.20

2.03 (8.07%)

10:11
12/10/19
12/10
10:11
12/10/19
10:11
Conference/Events
Stitch Fix management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

CHWY

Chewy

$24.93

0.76 (3.14%)

10:10
12/10/19
12/10
10:10
12/10/19
10:10
On The Fly
Investors weigh Chewy's IPO lockup expiry against better than expected sales »

Shares of Chewy.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

RST

Rosetta Stone

$16.55

0.075 (0.46%)

10:09
12/10/19
12/10
10:09
12/10/19
10:09
Conference/Events
Rosetta Stone management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RPAI

Retail Properties of America

$13.90

0.02 (0.14%)

10:07
12/10/19
12/10
10:07
12/10/19
10:07
Conference/Events
Retail Properties of America management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 19

    Feb

PYPL

PayPal

$104.01

0.25 (0.24%)

10:06
12/10/19
12/10
10:06
12/10/19
10:06
Conference/Events
PayPal management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

QTT

Qutoutiao

$2.75

-0.11 (-3.85%)

10:06
12/10/19
12/10
10:06
12/10/19
10:06
Hot Stocks
Breaking Hot Stocks news story on Qutoutiao »

Qutoutiao drops 8% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PWFL

PowerFleet

$5.90

(0.00%)

10:05
12/10/19
12/10
10:05
12/10/19
10:05
Conference/Events
PowerFleet management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

QTT

Qutoutiao

$2.74

-0.12 (-4.20%)

10:05
12/10/19
12/10
10:05
12/10/19
10:05
Periodicals
Breaking Periodicals news story on Qutoutiao »

Wolfpack Research says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$18.86

-0.06 (-0.32%)

10:05
12/10/19
12/10
10:05
12/10/19
10:05
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:05
12/10/19
12/10
10:05
12/10/19
10:05
General news
The FOMC began its 2-day meeting »

The FOMC began its 2-day…

PRFT

Perficient

$42.14

-0.2 (-0.47%)

10:04
12/10/19
12/10
10:04
12/10/19
10:04
Conference/Events
Perficient management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

BAESY

BAE Systems

$0.00

(0.00%)

10:01
12/10/19
12/10
10:01
12/10/19
10:01
Hot Stocks
BAE Systems awarded DARPA contract to develop new cyber tools »

BAE Systems has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.